|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000118257 |
Summary for NRP2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000118257 | Gene symbol | NRP2 |
| Gene name | neuropilin 2 | |
| HGNC | 8005 | |
| Entrez ID | 8828 | |
| Gene type | protein_coding | |
| Synonyms | NRP2|VEGF165R2 | |
| UniProtAcc | O60462 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000118257 | NRP2 | DB16453 | ATYR1923 | BiotechDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NRP2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NRP2 | 2.20e+03 | -2.26e+00 | 4.78e-01 | -4.73e+00 | 2.22e-06 | 1.58e-05 | BLCA |
| NRP2 | 1.27e+03 | -1.32e+00 | 2.73e-01 | -4.84e+00 | 1.30e-06 | 4.80e-06 | COAD |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NRP2 | 1.52e+03 | -1.70e+00 | 4.60e-01 | -3.69e+00 | 2.22e-04 | 9.51e-04 | READ |
Top |
Sex-biased somatic mutation for NRP2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NRP2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg22367989 | chr2:205681936 | CGI:chr2:205681879-205682842 | promoter | 7.66e-02 | 2.61e-01 | -2.29e+00 | 2.20e-02 | 3.63e-02 | -1.84e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg01154445 | chr2:205683447 | CGI:chr2:205681879-205682842 | promoter,gene body | 2.42e-01 | 1.09e-01 | 2.34e+00 | 1.95e-02 | 2.34e-02 | 1.33e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg01154445 | chr2:205683447 | CGI:chr2:205681879-205682842 | promoter,gene body | 4.89e-01 | 3.46e-01 | 5.67e+00 | 1.43e-08 | 3.15e-08 | 1.43e-01 |
Top |
Exon skipping events with PSI in TCGA for NRP2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NRP2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NRP2 |
| TFs related to NRP2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PCPG | GATA3 | NRP2 | 4.53e+00 | 9.84e-01 | 3.71e+00 | 9.31e-03 | Male-biased |
| PCPG | IRF6 | NRP2 | 5.13e+00 | 9.82e-01 | 4.41e+00 | 1.52e-02 | Male-biased |
| PCPG | ONECUT1 | NRP2 | 4.58e+00 | 9.85e-01 | 3.73e+00 | 8.26e-03 | Male-biased |
| PCPG | SOX7 | NRP2 | 3.92e+00 | 9.82e-01 | 2.53e+00 | 5.50e-04 | Male-biased |
| PCPG | UNCX | NRP2 | 4.23e+00 | 9.88e-01 | 3.03e+00 | 1.52e-03 | Male-biased |
| NRP2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NRP2 |
| RBPs related to ES in NRP2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NRP2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs13424127 | chr2:212416523:T:C | - | 0.227729057400633 | 0.0359102180499345 | GBM | Female-baised eQTL |
| rs13385225 | chr2:212416588:A:G | - | 0.227729057400633 | 0.0359102180499345 | GBM | Female-baised eQTL |
| rs77959765 | chr2:212417370:T:G | - | 0.227729057400633 | 0.0359102180499345 | GBM | Female-baised eQTL |
| rs13408977 | chr2:212405124:G:A | - | 0.229723485446645 | 0.0378188535624778 | GBM | Female-baised eQTL |
| rs79264447 | chr2:212419234:G:A | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs13387495 | chr2:212420333:T:C | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs1505348 | chr2:212426598:C:A | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs1505349 | chr2:212426782:A:C | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs10193290 | chr2:212427095:G:A | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs78063670 | chr2:212431127:C:T | - | 0.225789771013262 | 0.0423860970825399 | GBM | Female-baised eQTL |
| rs115951538 | chr2:205073977:A:C | - | 0.159093188099752 | 0.0204135207972116 | SARC | Female-baised eQTL |
| rs79024572 | chr2:205080242:G:T | - | 0.158394383015432 | 0.0221176616009184 | SARC | Female-baised eQTL |
| rs139976161 | chr2:208787136:A:T | - | 0.0839476957802333 | 0.0149587436179237 | LUAD | Female-baised eQTL |
| rs115823494 | chr2:208790279:G:T | - | 0.0839476957802333 | 0.0149587436179237 | LUAD | Female-baised eQTL |
| rs76571384 | chr2:208792538:C:G | - | 0.0839476957802333 | 0.0149587436179237 | LUAD | Female-baised eQTL |
| rs114159053 | chr2:208784699:C:G | - | 0.0840724332045599 | 0.0166453411625769 | LUAD | Female-baised eQTL |
| rs77755740 | chr2:208818892:C:T | - | 0.0812147525597442 | 0.0222731627619623 | LUAD | Female-baised eQTL |
| rs978469 | chr2:208794322:T:C | - | 0.0790232992701924 | 0.0246255958565935 | LUAD | Female-baised eQTL |
| rs75258610 | chr2:208796712:A:G | - | 0.0794326367238558 | 0.0256613343392932 | LUAD | Female-baised eQTL |
| rs75591687 | chr2:208800024:C:T | - | 0.0794326367238558 | 0.0256613343392932 | LUAD | Female-baised eQTL |
| rs113461833 | chr2:208806641:G:A | - | 0.0794326367238558 | 0.0256613343392932 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs13396837 | chr2:214660265:C:T | - | 0.249908661651819 | 0.00210919935506321 | GBM | Male-baised eQTL |
| rs35437698 | chr2:214667560:C:G | - | 0.249908661651819 | 0.00210919935506321 | GBM | Male-baised eQTL |
| rs12620862 | chr2:214668089:T:G | - | 0.249908661651819 | 0.00210919935506321 | GBM | Male-baised eQTL |
| rs1012165 | chr2:201646207:C:T | - | 0.0901049696564819 | 0.0218837734901374 | LGG | Male-baised eQTL |
| rs13036106 | chr2:198173113:C:G | - | -0.0515469045102771 | 0.0173777635706048 | BLCA | Male-baised eQTL |
| rs11890712 | chr2:198174104:T:A | - | -0.04983814672778 | 0.0266907939407618 | BLCA | Male-baised eQTL |
| rs1434292 | chr2:198174105:A:T | - | -0.04983814672778 | 0.0266907939407618 | BLCA | Male-baised eQTL |
| rs961805 | chr2:204727004:C:T | - | 0.0579705706338066 | 0.00350194192192096 | LUAD | Male-baised eQTL |
| rs80345797 | chr2:204724849:G:A | - | 0.0619254731034405 | 0.00579307412689662 | LUAD | Male-baised eQTL |
| rs28366983 | chr2:204726452:C:T | - | 0.0526968771565745 | 0.00994162066843112 | LUAD | Male-baised eQTL |
| rs7595278 | chr2:204687868:G:A | - | 0.068898722909582 | 0.014435347457293 | LUAD | Male-baised eQTL |
| rs10804139 | chr2:204512982:A:G | - | -0.047837209424436 | 0.0368478542978265 | LUAD | Male-baised eQTL |
| rs7590658 | chr2:204510410:G:A | - | -0.0475491125466242 | 0.041997972848604 | LUAD | Male-baised eQTL |
| rs2887915 | chr2:210689850:C:T | - | 0.0555947966359964 | 0.00640574261864416 | COAD | Male-baised eQTL |
| rs5002316 | chr2:210680500:T:C | - | 0.0538098830402676 | 0.0155532134342886 | COAD | Male-baised eQTL |
| rs4142153 | chr2:210681194:C:G | - | 0.0532682040780477 | 0.0171504077514827 | COAD | Male-baised eQTL |
| rs1521646 | chr2:212179530:G:C | - | 0.0520161179711986 | 0.0174977448335611 | COAD | Male-baised eQTL |
| rs17416799 | chr2:212184710:A:G | - | 0.0520021336141004 | 0.0192620594524986 | COAD | Male-baised eQTL |
| rs10171279 | chr2:210683362:G:C | - | 0.0496935768742369 | 0.0219177431887944 | COAD | Male-baised eQTL |
| rs11887861 | chr2:210683969:C:A | - | 0.0496935768742369 | 0.0219177431887944 | COAD | Male-baised eQTL |
| rs2371015 | chr2:210684885:C:T | - | 0.0496935768742369 | 0.0219177431887944 | COAD | Male-baised eQTL |
| rs11693640 | chr2:212181454:T:C | - | 0.0504018785080184 | 0.0237135323492363 | COAD | Male-baised eQTL |
| rs12052282 | chr2:212180515:A:C | - | 0.0501102935002441 | 0.0260892175497294 | COAD | Male-baised eQTL |
| rs10195020 | chr2:210792502:T:G | - | 0.0480010719817588 | 0.0280911587103235 | COAD | Male-baised eQTL |
| rs13407289 | chr2:212204009:C:T | - | 0.0477467798777695 | 0.032897458069812 | COAD | Male-baised eQTL |
| rs17344880 | chr2:212181891:C:T | - | 0.0486000229724866 | 0.0351668448978764 | COAD | Male-baised eQTL |
| rs1521661 | chr2:212218379:T:A | - | 0.0466149262515484 | 0.0364152596780556 | COAD | Male-baised eQTL |
| rs10048673 | chr2:212218557:A:G | - | 0.0466149262515484 | 0.0364152596780556 | COAD | Male-baised eQTL |
| rs4142152 | chr2:210681319:C:T | - | 0.0500583308201721 | 0.0409650823050548 | COAD | Male-baised eQTL |
| rs35863145 | chr2:210682605:G:A | - | 0.0500583308201721 | 0.0409650823050548 | COAD | Male-baised eQTL |
| rs4310998 | chr2:210687165:C:T | - | 0.0497513650071721 | 0.044062798850866 | COAD | Male-baised eQTL |
| rs2371016 | chr2:210687220:G:C | - | 0.0497513650071721 | 0.044062798850866 | COAD | Male-baised eQTL |
| rs9288420 | chr2:210687897:G:A | - | 0.0497513650071721 | 0.044062798850866 | COAD | Male-baised eQTL |
| rs2371018 | chr2:210689997:T:C | - | 0.0497513650071721 | 0.044062798850866 | COAD | Male-baised eQTL |
| rs10194936 | chr2:210683713:A:G | - | 0.0496560436542822 | 0.0441718860546168 | COAD | Male-baised eQTL |
| rs12623361 | chr2:210680242:C:T | - | 0.0494801169871988 | 0.0455328560867702 | COAD | Male-baised eQTL |
| rs4375810 | chr2:212229687:T:C | - | 0.0451505733261231 | 0.0457377796218453 | COAD | Male-baised eQTL |
| rs4673654 | chr2:212228678:C:A | - | 0.0450492318487332 | 0.0465724716700867 | COAD | Male-baised eQTL |
| rs11694300 | chr2:212227303:T:C | - | 0.0449407412983893 | 0.0486491552306123 | COAD | Male-baised eQTL |
| rs11677095 | chr2:212227355:A:G | - | 0.0449407412983893 | 0.0486491552306123 | COAD | Male-baised eQTL |
| rs883501 | chr2:205791940:A:T | gene | 0.0618295240950759 | 0.0487616545240095 | COAD | Male-baised eQTL |
| rs11689207 | chr2:210754847:A:G | - | 0.0474537070416514 | 0.048827837599252 | COAD | Male-baised eQTL |
| rs10048819 | chr2:212225956:T:G | - | 0.0449886033418599 | 0.0493635953703783 | COAD | Male-baised eQTL |
| rs7560301 | chr2:212226873:C:T | - | 0.0449886033418599 | 0.0493635953703783 | COAD | Male-baised eQTL |
| rs11676942 | chr2:212226991:A:T | - | 0.0449886033418599 | 0.0493635953703783 | COAD | Male-baised eQTL |
| rs59602419 | chr2:210683096:A:G | - | 0.0491177374476276 | 0.0497217044995762 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000118257 |
| CpG Site: cg17455088 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.210073139983216 | |
 | Gene ID: ENSG00000118257 |
| CpG Site: cg05025612 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: - | |
| Female Effect: 0.100696918911421 | |
 | Gene ID: ENSG00000118257 |
| CpG Site: cg09343667 | |
| Position to Gene: gene | |
| Male Effect: -0.326462066129936 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg09343667 | chr2:205707332 | gene | -0.326462066129936 | 7.99164217704584e-07 | -0.32978379731871577 | 9.27390302580898e-09 | LGG |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg17455088 | chr2:205686742 | gene,enhancer | -0.210073139983216 | 1.25411794586234e-09 | -0.41996165469249647 | 2.5667581069234302e-12 | LUAD |
| cg05025612 | chr2:205776364 | gene,exon,CDS | 0.100696918911421 | 6.31132930220972e-05 | 0.45698051067978307 | 1.7493797648477572e-07 | LIHC |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NRP2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000118257 | NRP2 | C0004352 | Autistic Disorder | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0022333 | Jacksonian Seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0036572 | Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0149958 | Complex partial seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0234533 | Generalized seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0234535 | Clonic Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0270824 | Visual seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0270844 | Tonic Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0270846 | Epileptic drop attack | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0422850 | Seizures, Somatosensory | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0422852 | Seizures, Auditory | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0422853 | Olfactory seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0422854 | Gustatory seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0422855 | Vertiginous seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0494475 | Tonic - clonic seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751056 | Non-epileptic convulsion | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751110 | Single Seizure | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751123 | Atonic Absence Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751494 | Convulsive Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751495 | Seizures, Focal | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C0751496 | Seizures, Sensory | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C3495874 | Nonepileptic Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C4048158 | Convulsions | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C4316903 | Absence Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C4317109 | Epileptic Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C4317123 | Myoclonic Seizures | 1 | CTD_human |
| ENSG00000118257 | NRP2 | C4505436 | Generalized Absence Seizures | 1 | CTD_human |
